Company Overview and News
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
A McDermott International, Inc. (MDR - Free Report) -led consortium, which includes Baker Hughes, a GE company (BHGE - Free Report) , recently received a contract from the South Korean company, POSCO DAEWOO Corp. for developing the Shwe gas field, offshore Myanmar. The consortium will help POSCO with the second phase of the development program for the field located off the coast of Western Myanmar.
BHI DK GM.WS.A GM.WS.B BHGE GM.WS.C MDR GM GM.WSB CEO
McDermott International, Inc. (NYSE: MDR) and Baker Hughes, a GE company (NYSE: BHGE), have announced the award of a contract by POSCO DAEWOO Corp. for phase two of the Shwe gas field development offshore Western Myanmar.
BHI BHGE MDR MCDFF
A consortium of McDermott International, Inc. and Baker Hughes, a GE company (BHGE) has won a contract from POSCO DAEWOO Corp. for the second phase of the Shwe gas field development offshore Western Myanmar, McDermott reported Wednesday.
BHI MDR MCDFF
TULSA, Okla., June 26, 2018 (GLOBE NEWSWIRE) -- Matrix Service Company (Nasdaq:MTRX) — Matrix Service Company (Nasdaq:MTRX) today announced that it has appointed Liane K. Hinrichs to serve as a member of its Board of Directors following a temporary increase in Board size from seven to eight members. Ms. Hinrichs term commenced on June 5, 2018. The size of the Board will revert to seven when Board Chairman Tom E.
MTRX MDR MCDFF
Investors focused on the Oils-Energy space have likely heard of McDermott International (MDR - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? Let's take a closer look at the stock's year-to-date performance to find out.
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
Halliburton’s (HAL) implied volatility was 25.2% on June 1. On April 23, the day Halliburton released its first-quarter earnings, its implied volatility was 24.9%. Since then, Halliburton’s implied volatility has increased marginally. Halliburton accounts for 3.1% of the SPDR S&P Oil & Gas Equipment & Services ETF (XES). XES provides exposure to the energy sector’s oil and gas equipment and services segment.
WFT MDR MCDFF
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C,V.2 P(&]B:@T\/"],:6YE87)I>F5D(#$O3" Q M-#$R,C$O3R S-S$O12 Y.# U-2].(#[email protected],30P.#[email protected]@6R T.3,@,C4U M73X^#65N9&]B:@[email protected](" @(" @(" @(" @#0HS.#[email protected],"!O8FH-/#PO1&5C;V1E M4&%R;7,\/"]#;VQU;6YS(#4O4')E9&EC=&]R(#$R/CXO1FEL=&5R+T9L871E M1&5C;V1E+TE$6SQ#1C$U-S0X.$8W,C%[email protected] M,S9=+TEN9F\@,S8X(# @4B],[email protected]@.#,O4')E=B Q-# X,34O4F]O=" S M-S @,"!2+U-I>[email protected]# U+U1Y<&4O6%)E9B][email protected],R Q73X^
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C$R-R P(&]B:@T\/"],:6YE87)I>F5D(#$O3" Q M,3 U.# O3R Q,CDO12 R,S4V.2].(#,O5" Q,3 R,3DO2"!;(#0X," R,3== M/CX-96YD;V)J#2 @(" @(" @(" @(" @#0HQ-# @,"!O8FH-/#PO1&5C;V1E M4&%R;7,\/"]#;VQU;6YS(#0O4')E9&EC=&]R(#$R/CXO1FEL=&5R+T9L871E M1&5C;V1E+TE$6SPP1C1$,3%&.4(S,#DT,C0V04%"-S)#0T,S0CA&-48Q1CX\ M0D4U-#5#,D%",T$Q,D4T,SA$030P0C W.#A!,38R-S$^72]);F1E>%LQ,C<@ M,C==+TEN9F\@,3(V(# @4B],[email protected]@-S$O4')E=B Q,3 R,C O4F]O=" Q M,[email protected]@,"!2+U-I>[email protected],34T+U1Y<&4O6%)E9B][email protected],B Q73X^ M(P,3+P 5D,#(QD$/\9X[X"[email protected] [VT*&0T*96YD
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
Silicon Investor Message Boards
This table lists all message boards related to MDR / McDermott International, Inc. on message board site Silicon Investor.
|MDRX: Allscripts, Inc.||MDR: McDermott International|
|Medical Resorts International Inc (MDRE)||Allscripts Inc-(MDRX)|
as of ET